Synthetic cannabinoids: the multi-organ failure and metabolic derangements associated with getting high

References

• Dewey WL. Cannabinoid pharmacology. Pharmacol Rev. 1986; 38: 151–78.
   PubMed Web of Science ®Google Scholar
• Rosenbaum CD, Carreiro SP, Babu KM. Here today, gone tomorrow … and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, salvia divinorum, methoxetamine, and piperazines. J Med Toxicol. 2012; 8: 15–32.
   PubMedGoogle Scholar
• Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 39: 234–43.
   PubMed Web of Science ®Google Scholar
• Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics. 2011; 128: 1622–7.
   PubMed Web of Science ®Google Scholar
• Durand D, Delgado LL, de la Parra-Pellot DM, Nichols-Vinueza D. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use. Clin Schizophr Relat Psychoses. 2013; 8: 1–13.
   Google Scholar
• Ukaigwe A, Karmacharya P, Donato A. A gut gone to pot: A case of cannabinoid hyperemesis syndrome due to K2, a synthetic cannabinoid. Case Rep Emerg Med. 2014; 2014: 167098.
   PubMedGoogle Scholar
• Yücel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C, etal. Regional brain abnormalities associated with long-term heavy cannabis use. Archives of General Psychiatry. 2008; 65: 694–701.
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse Research. Synthetic marijuana third most reported substance used by U.S. high school students. CESAR Fax. 2013; 22(17): http://www.cesar.umd.edu/cesar/cesarfax/vol22/22-17.pdf..
   Google Scholar
• McSherry JW. Spice, pot, and stroke. Neurology. 2014; 82: 2147.
   Web of Science ®Google Scholar
• Freeman MJ, Rose DZ, Myers MA, Gooch CL, Bozeman AC, Burgin WS. Ischemic stroke after use of the synthetic marijuana “spice”. Neurology. 2013; 81: 2090–3.
   PubMed Web of Science ®Google Scholar
• Tanei T, Morita Y, Yashima A, Wakita H, Takebayashi S, Nakahara N, etal. [Severe rhabdomyolysis and intracranial hemorrhage associated with synthetic cannabinoid: A case report]. No Shinkei Geka. 2014; 42: 867–71.
   Google Scholar
• Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: What cardiologists need to know. Am J Cardiol. 2014; 113: 187–90.
   PubMed Web of Science ®Google Scholar
• Gottschalk LA, Aronow WS, Prakash R. Effect of marijuana and placebo-marijuana smoking on psychological state and on psychophysiological cardiovascular functioning in angina patients. Biol Psychiatry. 1977; 12: 255–e266.
   PubMed Web of Science ®Google Scholar
• Ting JYS. Reversible cardiomyopathy associated with acute inhaled marijuana use in a young adult. Clin Toxicol (Phila). 2007; 45: 432–4.
   PubMed Web of Science ®Google Scholar
• Kaushik M, Alla VM, Madan R, Arouni AJ, Mohiuddin SM. Recurrent stress cardiomyopathy with variable regional involvement: Insights into etiopathogenetic mechanisms. Circulation. 2011; 124: 556–7.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Rajesh M, Bátkai S, Patel V, Kashiwaya Y, Liaudet L, etal. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res. 2010; 85: 773–84.
   PubMed Web of Science ®Google Scholar
• El-Subbagh H, Wittig T, Decker M, Elz S, Nieger M, Lehmann J. Dopamine/serotonin receptor ligands. Part IV [1]: Synthesis and pharmacology of novel 3-benzazecines and 3-benzazonines as potential 5-HT2A and dopamine receptor ligands. Arch Pharm (Weinheim). 2002; 335: 443–8.
   Web of Science ®Google Scholar
• Fisar Z. Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch Pharmacol. 2010; 381: 563–72.
   PubMed Web of Science ®Google Scholar
• Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: Clinical and laboratory findings. Addiction. 2013; 108: 534–44.
   PubMed Web of Science ®Google Scholar
• Bhanushali GK, Jain G, Fatima H, Leisch LJ. Thornley-Brown D. AKI associated with synthetic cannabinoids: A case series. Clin J Am Soc Nephrol. 2013; 8: 5236.
   Web of Science ®Google Scholar
• Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S, etal. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One. 2009; 4: e5844.
   PubMed Web of Science ®Google Scholar